Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.

ABSTRACT: Aim: A systematic review and network meta-analysis (NMA) was performed to evaluate the efficacy of first-line treatments for locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) patients.Materials & methods: Databases were searched for randomized controlled trials evaluating first-line treatments for locally recurrent unresectable or metastatic TNBC patients. NMA was performed to estimate relative treatment effects on overall and progression-free survival between pembrolizumab + chemotherapy and other interventions.Results: NMA including eight trials showed that the relative efficacy of pembrolizumab + chemotherapy was statistically superior to that of other immunotherapy- or chemotherapy-based treatment regimens.Conclusion: Pembroli

SUBMITTER: Haiderali A 

PROVIDER: S-EPMC11457619 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature